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Supplementary Materials 
Supplementary Methods 
HIV-1-infected subjects 
Purified IgG from donor EB354 ranked in the top 1% for neutralization breadth and 
potency in a cohort of 394 HIV-1 infected long-term non-progressors. This donor was 
diagnosed with HIV-1 Clade B in 1986. He received treatment with didanosine and stavudine 
between 1995 and 1998, but has had no antiretroviral therapy since that time. In 2002 his 
viral load was <400 copies/mL and CD4 and CD8 counts were 954 and 1046 cells/mm3, 
respectively. He had three documented peaks in viremia between 2002 and 2006. HLA 
typing revealed HLA A*01:01, 24:02, B*27:05, 57:01, C*01:02, 06:02. 
 
ELISAs 
High-binding 96-well ELISA plates (Costar) were coated overnight with 5 µg/mL  of 
purified 2CC core, gp120.YU2 (wild type or mutants) or gp140.YU2 foldon trimer (24) in 
PBS. After washing 6 times with PBS + 0.05 % Tween 20, the plates were blocked for 2 h 
with 2% BSA, 1 µM EDTA and 0.05% Tween-PBS (“blocking buffer”), and then incubated 
for 1 h with IgGs that were added as seven consecutive 1:4 dilutions in PBS from an initial 
concentration of 4 µg/mL. After additional washing, the plates were developed by incubation 
with goat HRP-conjugated anti-human IgG antibodies (Jackson ImmunoResearch) (at 0.8 
µg/mL  in blocking buffer) for 1 h followed by HRP chromogenic substrate (ABTS solution; 
Invitrogen). All experiments were performed at least 3 times.  
 For ELISAs using BG505 SOSIP.664 trimers with a D7324 epitope tag (BG505 
SOSIP.664-D7324 (26)) the plates were coated overnight with 5 µg /mL  of D7324 antibody 
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as previously described(26), and then washed and incubated with 500 ng/mL  of the trimer 
(22, 26). After a further wash, IgGs were added for 1 h as seven consecutive 1:4 dilutions in 
PBS from initial concentrations of 4 µg/mL . The endpoint was generated by incubation with 
goat HRP-conjugated anti-human IgG antibodies, as described above. All experiments were 
performed at least 3 times.  
For competitive ELISAs, the plates were coated with 0.5 µg/mL BG505.SOSIP.664 
(26), washed, blocked for 2 h with blocking buffer and then incubated for 1 h with competing 
antibodies added as seven consecutive 1:4 dilutions in PBS from an initial concentration of 
32 µg/mL, and in the presence of biotinylated BG1 or BG18 at a constant concentration of 4 
µg/mL. The plates were then incubated for 1 h with HRP-congugated streptavidin (Jackson 
ImmunoReseach) at 1 µg/mL in blocking buffer, followed by HRP chromogenic substrate 
(ABTS solution; Invitrogen). All experiments were performed at least 3 times.  
 
HIV-1YU2 envelope mutants 
Single, double and triple mutations were introduced into wild-type HIV-
1YU2 envelope using the QuikChange (multi-) site-directed mutagenesis kit, according to the 
manufacturer’s specifications (Agilent Technologies). 
Protein Production and Purification for structural studies. 
6x-His-tagged BG18, BG18N26Q, NC102, and NC37 Fabs were expressed by transient 
transfection in HEK293-6E cells and purified from transfected cell supernatants using Ni2+-
NTA affinity chromatography (GE Healthcare) and Superdex 200 16/60 size exclusion 
chromatography (SEC) (GE Healthcare). Truncated, His-tagged 93TH057 gp120 core protein 
was produced in baculovirus-infected insect cells and purified as described using Ni2+ 
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affinity chromatography (GE Healthcare) (44, 92). Prior to crystallization trials, purified 
NC37 and 93TH057 proteins were coincubated (2:1 molar ratio of Fab to gp120 core) and 
treated with 5 kU of Endoglycosidase H per mg of gp120 protein for 3 h at 25°C. 
Endoglycosidase H-treated complex was purified by size exclusion chromatography using a 
Superdex 200 10/300 GL column (GE Healthcare). 
Soluble BG505 SOSIP.664 trimers for EM studies were constructed as described 
(26). HEK293-6E cells treated with 5 µM kifunensine (Sigma) were co-transfected with 
plasmids encoding BG505 SOSIP.664 and soluble furin at a ratio of 4:1. BG505 SOSIP.664 
protein was harvested from cell supernatants using a 2G12 immunoaffinity column made by 
covalently coupling 2G12 IgG monomer to an NHS-activated Sepharose column (GE 
Healthcare). Protein was eluted with 3 M MgCl2 followed by immediate buffer exchange into 
Tris-buffered saline (TBS) pH 7.4 (50 mM NaCl). Trimers were further purified using Mono 
Q 5/50 GL (GE Healthcare) followed by Superose 6 10/300 SEC (GE Healthcare). 
 
Negative-stain single particle EM 
Purified BG505 SOSIP.664–BG18–179NC75 complexes were diluted to 10 µg/mL  
in TBS immediately before adding 3 µL to a glow-discharged ultrathin C film on holey 
carbon support film, 400 mesh, Cu grids (Ted Pella, Inc.). Samples on the grids were cross-
linked using glutaraldehyde vapor and then stained with 3% uranyl acetate. Data were 
collected using a FEI Tecnai T12 transmission electron microscope operating at 120 keV 
equipped with a Gatan Ultrascan 2k X 2k CCD. Images were acquired using a 0.5 s exposure 
time at a nominal magnification of 42,000x at 1 µm defocus, resulting in 2.5 Å per pixel. A 
total of 25639 particles were picked using swarm picking in EMAN2.1 (90), and the CTF 
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correction was done using EMAN2.1 (90). Initial reference-free 2D class averaging was 
performed using RELION and all particles were sorted into 250 classes. 9827 particles 
corresponding to good class averages were selected, and the particles were further sorted 
using 3D classification in RELION, after which 7925 particles are selected for refinement. 
To obtain a reference structure for 3D classification and refinement, we collected data from 
an independent BG505 SOSIP.664–BG18–179NC75 complex sample by cryoelectron 
tomography and obtained a 40 Å sub-tomogram averaged structure using previously-
described methods (93). The sub-tomogram averaged structure was low-pass filtered to 80 Å 
for use as the reference structure for single particle reconstruction. The resolution of the final 
single particle reconstruction was ~25 Å calculated using RELION (91) and a gold-standard 
FSC with a 0.143 cutoff as recommended for resolution estimations for single particle EM 
reconstructions (94).  
 
Fitting of EM density maps 
EM structures were visualized using USCF Chimera (95, 96). Coordinates from 
crystal structures were fit into the sub-tomogram averaged or negative stain single particle 
EM structures using the fit in map utility within UCSF Chimera with the following options: 
real-time correlation/average update, use map simulated from atoms, resolution 25 Å. We 
first fit a BG505 SOSIP.664 structure (PDB 4TVP) into the density, and then fit coordinates 
for BG18 Fab (this study) and CH103 Fab (PDB 4JAM; as a model for 179NC75 Fab) into 
corresponding densities individually. The CH1-CL domain regions of the Fabs exhibited poor 
densities, as expected given variability in Fab elbow angles (97).  
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Crystallization, X-ray data collection and structure determinations 
Crystals of BG18 Fab in which a potential N-linked glycosylation site at heavy chain 
position 26 was removed by mutating Asn26HC to Gln showed superior size and morphology 
compared with crystals of wild-type BG18 Fab, thus the structure determination was done 
using BG18N26Q Fab. Crystals of BG18N26Q Fab (space group P21; a = 46.12 Å, b = 71.04 Å, 
c = 69.54 Å; β = 98.48˚; 1 molecule per asymmetric unit); were obtained by combining 0.2 
µL of an 18 mg/mL  protein solution with 0.2 µL of 0.1 M sodium acetate pH 4.5, 26.8% 
(v/v) polyethylene glycol (PEG) 400 and 13.4% (w/v) PEG 8,000 at 20°C, cryoprotected in 
mother liquor supplemented with 20% (v/v) ethylene glycol, and flash cooled in liquid 
nitrogen. Crystals of NC102 Fab (space group P212121; a = 60.2 Å, b = 82.5 Å, c = 117.2 Å; 
1 molecule per asymmetric unit) were produced by vapor diffusion in sitting drops with a 
reservoir of 0.1 M sodium acetate trihydrate pH 4.6 and 2.0 M ammonium sulfate using 250 
nL drops with a 1.5:1 protein:reservoir ratio. Crystals were cryoprotected in mother liquor 
supplemented with 25% (v/v) ethylene glycol and flash cooled in liquid nitrogen. Crystals of 
a NC37–93TH057 complex (space group P212121; a = 63.6 Å, b = 67.4 Å, c = 210.4 Å; 1 
complex per asymmetric unit) were produced by vapor diffusion in 250 nL sitting drops by 
incubating protein and reservoir (comprising 0.1 M HEPES pH 7.5 and 20% (w/v) PEG 
10,000) at a 1.5:1 protein:reservoir ratio. Crystals were cryoprotected in mother liquor 
supplemented with 20% (w/v) PEG 400 and flash cooled in liquid nitrogen. 
X-ray diffraction data were collected at the Stanford Synchrotron Radiation 
Lightsource beamline 12-2 outfitted with a Pilatus 6M pixel detector (Dectris). XDS was 
used to index, integrate and scale the data (88). Crystals of BG18N26Q Fab diffracted to 1.5 Å, 
and the structure was solved by molecular replacement using 10-1074 Fab (PDB code 4FQ2) 
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VHVL with CDR loops removed and CH1CL as search models. The structure was refined 
using an iterative approach of refinement with Phenix (43) and manual model building in 
Coot (89). The final model of BG18N26Q Fab (Rwork = 18.0%, Rfree = 18.9%) had 98.3%, 1.7% 
and 0% of residues in the favored, allowed, and disallowed regions, respectively, of the 
Ramachandran plot. NC102 Fab diffracted to 1.6 Å, and the structure was solved by 
molecular replacement using a model of NIH45-46 (PDB code 3U7W) with VHVL with CDR 
loops removed and CH1CL as search models. The final model of NC102 Fab (Rwork = 18.0%, 
Rfree = 20.0%) had 98%, 2% and 0% of residues in the favored, allowed, and disallowed 
regions, respectively, of the Ramachandran plot. The NC37–93TH057 gp120 complex 
structure was solved by molecular replacement using search models of NC102 VHVL, CH1CL, 
and a truncated gp120 core (from PDB 3U7Y) as search models. The final model of the 
NC37–93TH057 complex (Rwork = 21.0%, Rfree = 26.0%) had 96%, 4% and 0% of residues in 
the favored, allowed, and disallowed regions, respectively, of the Ramachandran plot. Data 
collection and refinement statistics are presented in Table S5. 
 
TZM-bl assays of Env glycol-mutant viruses 
Pseudoviruses were generated by transfection of 293T cells (ATCC) with an HIV-1 
Env expressing plasmid and the Env-deﬁcient genomic backbone plasmid called pSG3ΔEnv 
(AIDSreagent.org), as described previously (86). Pseudoviruses were harvested 72 h post-
transfection for use in neutralization assays. Neutralizing activity was assessed using a single 
round of replication pseudovirus assay and TZM-Bl target cells (AIDSreagent.org), as 
described previously (86). Briefly, TZM-bl cells were seeded in a 96-well flat bottom plate. 
To this plate was added pseudovirus, which was preincubated with serial dilutions of 
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antibody for 1 h at 37°C. Luciferase reporter gene expression was quantified 72 h after 
infection upon lysis and addition of Bright-GloTM Luciferase substrate (Promega). To 
determine IC50 values, dose-response curves were ﬁt by nonlinear regression. All assays were 
performed in duplicate. 
 
Synthesis of the HIV-1 V3 glycopeptides 
The synthesis of the V3 glycopeptides derived from several HIV-1 strains was 
achieved by using a chemoenzymatic method consisting of automated solid-phase peptide 
synthesis of the GlcNAc-peptide precursor and subsequent enzymatic transglycosylation of 
the GlcNAc-peptide to provide the target glycopeptides, following the previously published 
procedures (98). The interactions between the biotinylated synthetic glycopeptides and the 
BG18 and BG8 IgG antibodies were evaluated by SPR using a BIAcore T200 system (GE 
Healthcare) at 25 ºC. Biotinylated glycopeptides were immobilized on neutravidin-coated 
CM5 sensor chips in HBS-P buffer (10 mM HEPES, 150 mM NaCl, P20 surfactant 0.05% 
v/v, pH 7.4) until 200 response unit (RU) was achieved. BG18, BG8, PGT121 or 10-1074 
were injected at two-fold series dilutions of concentration starting at 4 mM in BS-P buffer 
with a flow rate of 40 µL /min for 180 s. BS-P buffer with a flow rate of 40 µL/min was then 
injected for 120s to allow for dissociation. Regeneration was performed by injection of 3M 
MgCl2 with a flow rate of 50 µL/min for 3 min followed by injection of HBS-P buffer with a 
flow rate of 50 µL/min for 5 min. 	
 
Autologous plasma virus single genome sequencing primers sequences 
envB5out: 5’– TAGAGCCCTGGAAGCATCCAGGAAG 
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envB3out: 5’– TTGCTACTTGTGATTGCTCCATGT 
envB5in: 5’– TTAGGCATCTCCTATGGCAGGAAGAAG 
envB3in: 5’– GTCTCGAGATACTGCTCCCACCC 
 
Bioinformatic processing of MiSeq env-sequences 
  
Sequence adapters were removed using Cutadapt v1.8.3. Read assembly for each 
virus was performed in three steps. First, de novo assembly was performed using Spades 
v3.6.1 to yield long contig files. Contigs longer than 255 bp were subsequently aligned to an 
HIV envelope reference sequence and a consensus sequence was generated using Geneious 
8. Finally, reads were re-aligned to the consensus sequence to close gaps and a final 
consensus was generated. Sequences with double peaks (cutoff consensus identity for any 
residue < 75%) were omitted from downstream analysis. 
 
Analysis of viral evolution 
Alignments of env nucleotide sequences were generated using ClustalW (version 
2.11) (99) or via manual alignment using Geneious (version 8.1.6) sequence analysis 
software (100). Regions that could not be unambiguously aligned were removed from 
phylogenetic analysis and diversity calculations. Evolutionary model classes for maximum 
likelihood phylogenetic analyses were selected using jModelTest (101). Maximum likelihood 
phylogenetic trees were generated using PhyML (version 3) (102) with joint estimation of 
model parameter values and phylogenies. Pairwise genetic diversity was compared among 
samples using a two-sample U statistic test (103)in the DIVEIN webtool (104). 
 
Generation of CMV-Env viruses 
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CMV-env expression cassettes were generated according to an established protocol 
(36). Briefly, the CMV promoter was amplified from pcDNA 3.1D/V5-His-TOPO 
Expression vector using the primers: 
CMVenv 5’AGTAATCAATTACGGGGTCATTAGTTCAT 3’and  
CMVenv1A 5’CATAGGAGATGCCTAAGCCGGTGGAGCTCTGCTTATATAGACCTC 
3’. The PCR product was purified using the Macherey-Nagel PCR and Gel Purification Kit. 1 
ul of first round PCR product was amplified using primers: 
env1ATOPO 5’ CACC GGCTTAGGCATCTCCTATGGCAGGAAGAA 3’ and  
Rev19 5’ ACTTTTTGACCACTTGCCACCCAT 3’ in a 20 µL volume containing 1x High 
Fidelity Buffer, 2 mM MgSO4, 0.2 mM dNTPs, 0.5 units of High Fidelity Platinum and 0.2 
µM of each primer. Cycling conditions were 94° C, 2 min; (94° C, 15 s; 55° C 30 s; 68° C, 4 
min) x 35; 68° C, 10 min. The presence of env was validated by analysis on a 0.7% Agarose 
gel and the product was purified using the Macherey-Nagel Gel and PCR Purification Kit. 10 
ng of envelope and 0.5 ng of CMV were then subjected to overlapping PCR with primers 
CMVenv and Rev19 in triplicates. Total reaction volume 6 was 50 µL containing 1x High 
Fidelity Buffer, 0.2 µM MgS04, 0.2 mM dNTPs, 1 U of Platinum Taq High Fidelity and 0.4 
µM of each primer. PCR was carried out at 94°C, 2min; (94° C, 30 s; 60° C 30 s; 68° C, 
4min) x 25; 68°C, 10 min. 500 ng of CMV-env were co-transfected with pSG3Δenv in 6-
well plates into 293T cells and supernatant was harvested after 48 h. Supernatants were 
subjected to neutralization testing by TZM-bl as described above. 
 
Viral Outgrowth Cultures 
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Virus from donor EB354 was obtained by co-culture of patient peripheral blood 
mononuclear cells (PBMCs) with healthy donor PBMCs as previously described (37). 
Healthy donor PBMCs were obtained from patients by leukapheresis under study protocol 
MNU-0628 at Rockefeller University. All donors provided written informed consent before 
participation. Healthy donor PBMCs were pre-stimulated at a density of 5 x 106 cells/mL in 
IMDM containing 10% FBS, 1% Penicillin-Streptomycin and PHA at 1 µg/mL for 2-3 days 
at 37°C and 5% CO2. 6 x 106 of the stimulated donor PBMCs were then transferred to IMDM 
containing 10% FBS, 1% Penicillin-Streptomycin, 10 IU/mL IL-2 and 5 µg/mL polybrene 
and co-cultured with 5-10 x 106 EB354 PBMCs at 37°C and 5% CO2. Media was replaced 
weekly and the presence of p24 in culture supernatant was quantified by Lenti-X p24 Rapid 
Titer Kit (Clontech). Cultures exceeding 1 ng of p24 per mL of supernatant were frozen and 
stored at -80°C. Determination of tissue culture infectious dose 50 (TCID50) and subsequent 
testing for sensitivity of autologous viruses to different broadly neutralizing antibodies and 
autologous serum IgG was carried out using a TZM-bl neutralization assay according to 
established protocols (86). All neutralization assays were run in duplicate. 
 
  
	 11	
 
 
 
Supplementary Figures: 
 
Figure S1: Isolation of neutralizing antibody clones from donor EB354. (A) Upper 
panels: CD19 pre-enriched IgG+ memory B cells were stained with CD19 and with three 
non-native HIV-1 baits: 2CC core, gp140YU2 fold-on trimer and gp14092UG37.8 + 
gp140CZA79012 (gp140 A+C) fold-on trimmers, and one native bait BG505.SOSIP-AviB. The 
VH VL
NC37 1-2/1-46 K3-20 28.8 27.9 D N F G T R P V P G R G Y Y Y G M D V 19
NC133 1-46 K3-20 28 23.2 D N R G D R N V P G R G Y Y Y G M D V 19
NC102 1-2 K3-20 27.1 22.2 D N F G T R P V P G R G Y Y Y G M D V 19
AC40 1-46 K3-20 33.5 21.1 D N F G E S H - - - K G Y T Y G M D A 16
BG8 4-4 L3-25 25.4 20.5 N V I R V F G V I S L G E W F H Y G M D V 21
BG18 4-4 L3-25 21.2 17.7 N A I R I Y G V V A L G E W F H Y G M D V 21
BG33 4-4 L3-25 25 18.4 N A I R I Y G V V A L G E W F H Y G M D V 21
BG42 4-4 L3-25 23.7 19.4 N V I R V F G V I S L G E W F H Y G M D V 21
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populations in the blue insert represents cells that were single cell sorted and the numbers 
indicate the percent of cells that were bait positive out of the total IgG+ B cells. (B) Pie 
charts represent the total Ig sequences that were amplified from the single sorted cells from 
the corresponding FACS plot shown in (A). The number in the middle of the pies represents 
the total number of antibodies sequenced. White slices represent sequences that appeared 
only once and did not have any clonal relatives. The slices represent antibody clones and are 
proportional to the number of sequences in every clone. Gray shaded slices represent clones 
that were obtained in only one sort. Colored slices that represent antibody clones that were 
sorted with at least two different non-native baits. The clones marked with an asterisk are 
clones representative antibodies of which exhibited tier 2 neutralizing activity. These are 
represented by the variants NC37 (blue clone), BG18 (magenta clone) and BG1 (green 
clone). (C) Genetic characteristic of the 13 antibodies, representative variants from each of 
the three clones (blue, magenta and green) that showed neutralizing activity. The VH, VL and 
level of mutations, as well as the sequence of the CDRH3 (based on IMGT definition) are 
indicated.  
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Figure S2: Competitive ELISA. An equal amount of (4 µg/mL) of biotinylated BG18 (top) 
and BG1 (bottom) were assayed for binding in ELISA to BG505 SOSIP.664 in the presence 
of increasing amounts of various competing antibodies. Detection was performed using 
Streptavidin HRP. The black line indicates biotinylated antibody binding in the absence of 
competition.  
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Figure S3: NC37 Fab-gp120 complex structure. (A) 2.7 Å crystal structure of a NC37 Fab-
gp120 complex superimposed on an 8ANC134 Fab-gp120 complex structure (PDB 4RX4). 
(B) Close-up of the NC37 Fab-gp120 interface compared to the 8ANC134 Fab-gp120 
interface. (C) Side view of a BG505 trimer structure in surface representation (PDB 4TVP) 
with predicted epitopes for NC37 (purple), 8ANC134 (green) and NIH45-46 (orange) shown 
on one protomer (dark gray) of the trimer.  
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Figure S4: Sequence comparison between BG18, PGT121, and 10-1074. (A) and (C): 
Dendrogram of the sequences of the heavy chains and light chains, respectively, of PGT121, 
10-1074, the nine BG18 clonal variants, and their predicted germlines. (B) and (D): Amino 
acid sequence alignment of the heavy chains and the light chains CDRs, respectively. 
Positions common to PGT121/10-1074 and BG18 variants are highlighted. Gaps in 
alignment are shaded in gray. 
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Figure S5: BG18 antibody binding to synthetic HIV-1 V3 glycopeptides. Biotin-tagged 
V3 glycopeptides were immobilized on a neotravidin chip and BG18 IgG was used as the 
analyte. (A) Interaction between BG18 and a JR-FL mini-V3 glycopeptide carrying a 
Man9GlcNAc2 glycan at N301. (B) Interaction between BG18 and a JR-FL mini-V3 
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glycopeptide carrying a Man9GlcNAc2 glycan at N332. (C) Interaction between BG18 IgG 
and a JR-FL mini-V3 glycopeptide carrying a biantennary complex type N-glycan at N301. 
(D) Interaction between BG18 IgG and a JR-FL mini-V3 glycopeptide carrying a biantennary 
complex type N-glycan at N332. (E) Interaction between BG18 IgG and an A244 mini-V3 
glycopeptide carrying a Man9GlcNAc2 glycan at N334. (F) Interaction between BG18 IgG 
and a CAP45 mini-V3 glycopeptide carrying a Man9GlcNAc2 glycan at N334.  
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Figure S6: env SGS of plasma virus from donor EB354. (A) Pie charts representing the 
total env sequences amplified by single genome PCR for every collection time point. The 
total number of sequences obtained from every time point is denoted in the middle of the pie, 
and the different slices are proportional to the number of sequences. Black slices represent 
non-functional env sequences carrying either frame shifts or stop codons. Blue slice indicate 
functional full-length env carrying intact N332 PNGS. Red slice indicate functional full-
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2006-A4 31,250 <0.009 >20 0.579 71.67 18.153
2006-H7 156,250 >20 8.224 15.368 >200 0.104
2010-D10 10,687 0.793 >20 8.788 93.55 0.333
2014-C10 53,437 17.323 >20 4.634 98.31 2.211
2013-F2 18,275 14.943 >20 7.251 NT 0.215
2013-F5 112 3.198 NT NT NT 0.204
2013-D7 NT NT NT NT NT NT
2013-A9 69,877 4.617 >20 3.535 NT 0.406
2014-H4 13,975 1.495 >20 2.105 73.54 0.108
2014-D4 <50 NT NT NT NT NT
2014-A7 13,975 >20 >20 11.137 118.31 0.256
2013-C8 53,437 1.530 >20 14.042 NT 0.343
2013-C6 69,877 0.728 >20 8.124 NT 0.450
2013-B6 267,184 >20 >20 4.522 NT 0.424
2013-A1 18,275 0.858 >20 9.492 NT 0.476
2013-C10 10,687 1.601 >20 3.095 43.022 0.282
2014-G5 2,795 0.818 >20 10.012 22.747 NT
2014-F11 1,250 1.288 >20 16.417 73.89 0.141
2013-B2 10,687 19.099 >20 10.021 NT 0.307
2013-A8 13,975 15.242 >20 >20 NT 8.161
2014-G9 31,250 0.932 >20 3.235 23.022 0.237
2014-D9 91,376 >20 >20 10.741 >100 0.246
2014-C12 69,877 0.845 >20 5.500 136.43 0.189
2014-B12 13,975 >20 >20 3.841 112.43 0.072
2013-F4 2,795 4.841 >20 3.372 NT 0.160
2013-A5 13,975 2.528 >20 3.683 NT 0.094
2010-G1 267,184 1.046 >20 8.998 138.21 0.314
2010-A7 13,975 2.703 >20 9.293 81.31 0.323
2010-B7 13,975 4.904 >20 9.063 120.52 0.399
2010-B1 69,877 5.007 NT 1.926 167.07 0.412
2010-B8 18,275 4.622 >20 12.621 80.91 0.287
2010-C12 53,437 3.858 >20 13.546 112.43 0.446
2010-D7 1,250 3.904 >20 10.174 96.85 0.188
2010-D9 3,655 4.394 >20 12.893 101.11 0.280
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length env where the PNGS in position N332 was mutated. (B) Maximum-likelihood 
phylogenetic tree of single genome–derived env gene sequences from donor EB354 sampled 
on 2006, 2010, 2013 and 2014. A red asterisk indicates clades with bootstrap support ≥90%. 
The table on the right side shows TCID50 values colored from dark blue (for high TCID50) to 
light blue (for low TCID50). IC50 values in TZM-bl assay of BG18, BG1, NC37, IgG from the 
contemporaneous serum and the control antibody 3BNC117 against autologous 
pseudoviruses using EB354 env sequences. A color key for IC50 is shown. 
  
 
 
Figure S7:  Viral loads in HIV-1YU2–infected, BG18- and NC37-treated humanized 
mice. (A) Viral load values in HIV1YU2–infected humanized mice before and after 
monotherapy with BG18 (top) and NC37 (bottom). The gray area on the graph indicates the 
period of time during which antibody was given. Each graph shows two independent 
  
experiments indicated by circles (one experiment) and by squares (second experiment). Filled 
and open symbols indicate treated and control mice, respectively. The dashed and solid red 
lines indicate the average values for control and treated mice, respectively.  
  
  
 
Figure S8: BG8 therapy in HIV1YU2–infected humanized mice. (A) Viral load values in 
four hu-mice before and after administration of BG8. The gray shaded area on the graph 
indicates the period of time during which antibody was administered. The bold red line 
  
indicate the geometric mean value (B) Amino acid sequence alignment of gp120 sequences 
from viruses cloned on day 21 after therapy. Each horizontal gray bar represents the 
sequence of a single gp120 clone aligned to HIV-1YU2. Amino acid substitutions are 
indicated as black ticks. The mouse ID from which the sequence was obtained is indicated on 
the vertical black bars. An expanded view of the boxed areas is shown on the right in each 
panel. (C) Pie chart showing the recurrent mutations in gp120 compared to the wild-type 
HIV-1YU2 sequence following BG8 therapy. The number in the center of the pie denotes the 
total number of sequences cloned; the slices represent the most consistently mutated areas in 
gp120 and are proportional to the number of sequences that carried mutations.  
 
 
Supplementary Tables: 
Table S1. Clinical information, donor EB354 
Table S2. IC50 and IC80 values in TZM-bl assay for antibodies NC37, BG1, BG18, BG8, 
and 10-1074 and PGT121 against a 118-virus panel 
Table S3. IC50 and IC80 values in TZM-bl assay of the 1:1:1 combination of NC37, BG1, 
and BG18 against a 118-virus panel 
Table S4.  IC50 and IC80 values in TZM-bl assay of antibodies BG8, BG18, PGT121, and 
12A12 against selected HIV-1 V3 envelop mutants.  
Table S5. Crystallization statistics 
